Explore journal overview, editorial leadership, indexing, articles in press, latest published work, and highlights from previous issues.
Cellular immunotherapy is an innovative treatment approach that provokes bodys own immune system to fight against the cancer. cellular immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, tumor-infiltrating lymphocytes (TIL) therapy, dendritic cell vaccine
Dendritic cell therapy: Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen.
CAR T-cell therapy: can be used to treat B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, transformed follicular lymphoma and follicular lymphoma.
TCR gene transfers: require human leukocyte antigen matching, can be used to treat several types of malignancies, including lung cancer, sarcomas and multiple myeloma.
TIL therapy: can be used to treat malignant melanoma, head and neck squamous cell carcinoma, genitourinary carcinoma and lung cancer.
Edelweiss: Cancer Open Access is an open access journal which aims to publish most complete and genuine source of information in the form of short commentary, mini review, case report, related, but not limited to above areas and making them available freely through online without any subscriptions and restrictions to researches worldwide
Researchers, authors, reviewers, and readers can use this page to find journal resources connected with Cellular immunotherapy, including published articles, related academic topics, current issue content, archive material, and manuscript submission information.
Related article links for Cellular immunotherapy will appear here as matching content is published in Edelweiss: Cancer Open Access (ISSN: 2689-6737). Readers can also browse the journal archive and current issue for connected research.
